Physician profile
Robert E Gardner
NPI 1346251436
$33,046.32
in general payments reported to CMS, 2019-2025
35 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,363 · 2020: $11K · 2021: $8,851 · 2022: $6,055 · 2023: $2,984 · 2024: $433 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,500 · Food and Beverage: $1,144 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,500.00 |
| Food and Beverage | $1,144.13 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $25,269.88 | 2019-2024 | |
| Abbvie INC. | $3,418.55 | 2021-2023 | |
| Ucb, INC. | $750.24 | 2019-2025 | Rystiggo, Nayzilam, Briviact |
| Biogen, INC. | $495.83 | 2019-2025 | Spinraza, Qalsody |
| Medtronic, INC. | $385.56 | 2022 | |
| Kyowa Kirin, INC. | $324.25 | 2019-2024 | Nourianz |
| Acadia Pharmaceuticals INC | $273.35 | 2019-2024 | Nuplazid |
| Emd Serono, INC. | $251.32 | 2019 | |
| Novartis Pharmaceuticals Corporation | $232.75 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $209.72 | 2020-2021 | |
| Eisai INC. | $165.84 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $155.47 | 2021-2022 | |
| Lundbeck LLC | $152.18 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $135.15 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $129.63 | 2023-2024 | Ingrezza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $110.88 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $88.09 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $59.72 | 2020-2022 | |
| Mdd US Operations, LLC | $55.63 | 2019-2020 | |
| Amgen INC. | $46.10 | 2019 | |
| Genzyme Corporation | $38.10 | 2019 | |
| Xeris Pharmaceuticals, INC. | $36.73 | 2021 | |
| Grifols USA, LLC | $32.92 | 2019-2021 | |
| Tanabe Pharma America, INC. | $29.81 | 2022 | |
| Sunovion Pharmaceuticals INC. | $29.20 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $21.99 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $19.99 | 2022 | |
| Lilly USA, LLC | $19.32 | 2020 | |
| Zyla Life Sciences, INC. | $19.05 | 2019 | |
| Genentech USA, INC. | $17.58 | 2023 | Ocrevus |
| Adamas Pharmaceuticals, INC. | $16.67 | 2020 | |
| Apria Healthcare LLC | $16.36 | 2021 | |
| Upsher-Smith Laboratories LLC | $16.12 | 2019 | |
| Acorda Therapeutics, INC | $16.09 | 2020 | |
| Sumitomo Pharma America, INC. | $6.25 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.